caa a22 4500 445853387 CHVBK 20180317145420.0 cr unu---uuuuu 170323e20110301xx s 000 0 eng 10.1007/s00204-010-0569-x doi (NATIONALLICENCE)springer-10.1007/s00204-010-0569-x Titanium dioxide inclusion in backing reduce the photoallergenicity of ketoprofen transdermal patch [Elektronische Daten] [Yang-Gyu Choi, Ji Lee, Il-Hong Bae, Young-Chang Ah, Han-Moe Ki, Jun-Ho Bae, Young-Ho Park, Kang Lee, Kyung-Min Lim] Ketoprofen (KP) is a widely used transdermal non-steroidal anti-inflammatory drug. However, increasing number of adverse effect case reports suggests that KP transdermal formulation can cause photoallergic reaction. The photoallergic potential of KP is attributable to the instability of KP under UV/visible light and subsequent formation of reactive degradation products. In this study, we investigated whether the inclusion of titanium dioxide (TiO2), a well-known mineral sunscreen agent, in the KP transdermal patch can prevent the photodegradation of KP and ultimately, can reduce photoallergic reaction. TiO2 inclusion in fabric backing effectively decreased the UV transmission through fabric patch throughout all UVA region from 320 to 380nm and consistently, KP patch with TiO2 exhibited significantly increased photostability of KP. This enhanced photostability of KP resulted in reduced generation of photodegradation product as determined by HPLC-UV analysis. In a good accordance with these in vitro results, photosensitization test in guinea pig in vivo demonstrated low photoallergic reactions of KP patch with TiO2 compared to KP patch without TiO2, indeed. This study demonstrated that KP transdermal patch with TiO2-included backing can provide with improved photostability and photosafety over conventional fabric KP patch. Springer-Verlag, 2010 Ketoprofen nationallicence Transdermal nationallicence Photoallergy nationallicence Phototoxicity nationallicence Photodegradation nationallicence Titanium dioxide nationallicence Choi Yang-Gyu Amorepacific Corporation R&D Center, 314-1, Bora-dong, Giheung-gu, 446-729, Yongin-si, Republic of Korea aut Lee Ji Amorepacific Corporation R&D Center, 314-1, Bora-dong, Giheung-gu, 446-729, Yongin-si, Republic of Korea aut Bae Il-Hong Amorepacific Corporation R&D Center, 314-1, Bora-dong, Giheung-gu, 446-729, Yongin-si, Republic of Korea aut Ah Young-Chang Amorepacific Corporation R&D Center, 314-1, Bora-dong, Giheung-gu, 446-729, Yongin-si, Republic of Korea aut Ki Han-Moe Amorepacific Corporation R&D Center, 314-1, Bora-dong, Giheung-gu, 446-729, Yongin-si, Republic of Korea aut Bae Jun-Ho Amorepacific Corporation R&D Center, 314-1, Bora-dong, Giheung-gu, 446-729, Yongin-si, Republic of Korea aut Park Young-Ho Amorepacific Corporation R&D Center, 314-1, Bora-dong, Giheung-gu, 446-729, Yongin-si, Republic of Korea aut Lee Kang Drug Targeting Laboratory, College of Pharmacy, SungKyunKwan University, 440-746, Jangan-gu, Suwon, Republic of Korea aut Lim Kyung-Min Amorepacific Corporation R&D Center, 314-1, Bora-dong, Giheung-gu, 446-729, Yongin-si, Republic of Korea aut Archives of Toxicology Springer-Verlag 85/3(2011-03-01), 219-226 0340-5761 85:3<219 2011 85 204 https://doi.org/10.1007/s00204-010-0569-x text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00204-010-0569-x text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Choi Yang-Gyu Amorepacific Corporation R&D Center, 314-1, Bora-dong, Giheung-gu, 446-729, Yongin-si, Republic of Korea aut NATIONALLICENCE 700 1- Lee Ji Amorepacific Corporation R&D Center, 314-1, Bora-dong, Giheung-gu, 446-729, Yongin-si, Republic of Korea aut NATIONALLICENCE 700 1- Bae Il-Hong Amorepacific Corporation R&D Center, 314-1, Bora-dong, Giheung-gu, 446-729, Yongin-si, Republic of Korea aut NATIONALLICENCE 700 1- Ah Young-Chang Amorepacific Corporation R&D Center, 314-1, Bora-dong, Giheung-gu, 446-729, Yongin-si, Republic of Korea aut NATIONALLICENCE 700 1- Ki Han-Moe Amorepacific Corporation R&D Center, 314-1, Bora-dong, Giheung-gu, 446-729, Yongin-si, Republic of Korea aut NATIONALLICENCE 700 1- Bae Jun-Ho Amorepacific Corporation R&D Center, 314-1, Bora-dong, Giheung-gu, 446-729, Yongin-si, Republic of Korea aut NATIONALLICENCE 700 1- Park Young-Ho Amorepacific Corporation R&D Center, 314-1, Bora-dong, Giheung-gu, 446-729, Yongin-si, Republic of Korea aut NATIONALLICENCE 700 1- Lee Kang Drug Targeting Laboratory, College of Pharmacy, SungKyunKwan University, 440-746, Jangan-gu, Suwon, Republic of Korea aut NATIONALLICENCE 700 1- Lim Kyung-Min Amorepacific Corporation R&D Center, 314-1, Bora-dong, Giheung-gu, 446-729, Yongin-si, Republic of Korea aut NATIONALLICENCE 773 0- Archives of Toxicology Springer-Verlag 85/3(2011-03-01), 219-226 0340-5761 85:3<219 2011 85 204 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer